<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02142244</url>
  </required_header>
  <id_info>
    <org_study_id>BCHNIR01</org_study_id>
    <nct_id>NCT02142244</nct_id>
  </id_info>
  <brief_title>Fluorescence Surgery for Sentinel Node Identification in Melanoma</brief_title>
  <official_title>Infrared Fluorescence Guided Surgery for Sentinel Node Identification in Cutaneous Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barretos Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Barretos Cancer Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sentinel node biopsy is a surgical procedure used to find melanoma lymph node metastasis
      (i.e. groin/axilla) in very early stages. This study aims to add a new technology over the
      standard procedure - a fluorescent contrast (indocyanine green) using special light (near
      infra-red) - looking for more precise diagnosis of the presence of the lymph node metastasis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objectives of this study is perform a new technique added to the usual procedure for
      sentinel lymph node biopsy for cutaneous melanoma. The fluorescence surgery consists in a
      injection of indocyanine green around the primary tumor, or, when already excised (excisional
      biopsy), the biopsy site at the beginning of the surgery. Patient performs, in a standard
      fashion, the lymph scintigraphy prior the surgery and is injected at the same time a blue die
      similarly the indocyanine green. Immediately after the indocyanine infusion, the injection
      site is massaged and a near infra red light (NIR) is focused over it. An appropriated infra
      red camera is positioned over the lymphatic pathway, searching for the fluorescence and
      localizing the sentinel node at the basin. The skin is opened and the sentinel node is
      resected. The success or not in localizing the sentinel node is pointed and the standard
      techniques are applied - gamma probe and surgical location of a blue lymph node. All sentinel
      node characteristics are noted as number, which technic identified it, time, location. Later
      information will be gathered as histological status, surgical complications, recurrence and
      survival.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sensibility of the sentinel node biopsy</measure>
    <time_frame>Time of surgery</time_frame>
    <description>The successful rate of the sentinel node localization and biopsy. The standard technique and the experimental one will be assessed</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Specificity of the sentinel node biopsy</measure>
    <time_frame>60 months</time_frame>
    <description>The false negative sentinel node biopsy rate. The proportion of patients submitted to the procedure with histological negative biopsy, presenting lymph node metastasis at follow up.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Overall survival</measure>
    <time_frame>60 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Disease free survival</measure>
    <time_frame>60 months</time_frame>
    <description>Presence and time to disease recurrence or not</description>
  </other_outcome>
  <other_outcome>
    <measure>Specific cancer survival</measure>
    <time_frame>60 months</time_frame>
    <description>Specific melanoma survival</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">318</enrollment>
  <condition>Melanoma</condition>
  <condition>Lymph Node Metastasis</condition>
  <arm_group>
    <arm_group_label>Near infra red sentinel node biopsy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sentinel node biopsy adding indocyanine green injection at the tumor/biopsy site during the surgical procedure to the standard technique (blue die and lymph scintigraphy) and near infra red light for fluorescence. The indocyanine green saline solution - 5mg diluted in 10ml. will be injected in 4 points around the biopsy site - 4ml each - total 0.8mg - single procedure.Near infra red lens and camera will be used to detect the fluorescence and localize the sentinel node for biopsy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Near infra red sentinel node biopsy</intervention_name>
    <description>Explicated in the protocol arm</description>
    <arm_group_label>Near infra red sentinel node biopsy</arm_group_label>
    <other_name>Sentinel node biopsy with fluorescence</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indocyanine green</intervention_name>
    <description>Explicated in the protocol arm</description>
    <arm_group_label>Near infra red sentinel node biopsy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Intraoperative Near-Infrared Imaging System</intervention_name>
    <description>Explicated in the protocol arm</description>
    <arm_group_label>Near infra red sentinel node biopsy</arm_group_label>
    <other_name>Photodynamic Eye (PDE)</other_name>
    <other_name>Pulsion</other_name>
    <other_name>MiniFlare</other_name>
    <other_name>The Flare Foundation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients eligible for sentinel node biopsy in standard care

        Exclusion Criteria:

          -  Previous neoplasia

          -  Previous surgery or scar in the lymph node basin or primary tumor, except primary
             tumor biopsy

          -  Local recurrence

          -  Hypersensibility or allergy history to indocyanine or Iodine-based contrast media
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vinicius L Vazquez, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Barretos Cancer Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barretos Cancer Hospital</name>
      <address>
        <city>Barretos</city>
        <state>SP</state>
        <zip>14784400</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Camila Crovador</last_name>
      <phone>+551733216600</phone>
      <phone_ext>6938</phone_ext>
      <email>camila.nap@hcancerbarretos.com.br</email>
    </contact>
    <contact_backup>
      <last_name>Vinicius L Vazquez, Ph.D.</last_name>
      <phone>+551733216600</phone>
      <phone_ext>6938</phone_ext>
      <email>viniciusvazquez@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Vinicius L Vazquez, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carlos EB Carvalho, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Tanaka E, Choi HS, Fujii H, Bawendi MG, Frangioni JV. Image-guided oncologic surgery using invisible light: completed pre-clinical development for sentinel lymph node mapping. Ann Surg Oncol. 2006 Dec;13(12):1671-81. Epub 2006 Sep 29.</citation>
    <PMID>17009138</PMID>
  </reference>
  <reference>
    <citation>Frangioni JV. New technologies for human cancer imaging. J Clin Oncol. 2008 Aug 20;26(24):4012-21. doi: 10.1200/JCO.2007.14.3065. Review.</citation>
    <PMID>18711192</PMID>
  </reference>
  <reference>
    <citation>Namikawa K, Yamazaki N. Sentinel lymph node biopsy guided by indocyanine green fluorescence for cutaneous melanoma. Eur J Dermatol. 2011 Mar-Apr;21(2):184-90. doi: 10.1684/ejd.2010.1237.</citation>
    <PMID>21498148</PMID>
  </reference>
  <reference>
    <citation>van der Vorst JR, Schaafsma BE, Verbeek FP, Swijnenburg RJ, Hutteman M, Liefers GJ, van de Velde CJ, Frangioni JV, Vahrmeijer AL. Dose optimization for near-infrared fluorescence sentinel lymph node mapping in patients with melanoma. Br J Dermatol. 2013 Jan;168(1):93-8. doi: 10.1111/bjd.12059.</citation>
    <PMID>23078649</PMID>
  </reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2014</study_first_submitted>
  <study_first_submitted_qc>May 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2014</study_first_posted>
  <last_update_submitted>February 1, 2017</last_update_submitted>
  <last_update_submitted_qc>February 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sentinel node biopsy</keyword>
  <keyword>Near infra red light</keyword>
  <keyword>Indocyanine green</keyword>
  <keyword>micrometastasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

